Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS

Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc‐receptor protects IgG from degradation, and a genetic polymorphism...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokkink, Willem‐Jan R., Haarman, Annechien E. G., Tio‐Gillen, Anne P., van Rijs, Wouter, Huizinga, Ruth, van Doorn, Pieter A., Jacobs, Bart C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931719/
https://www.ncbi.nlm.nih.gov/pubmed/27386503
http://dx.doi.org/10.1002/acn3.307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931719/
https://www.ncbi.nlm.nih.gov/pubmed/27386503
http://dx.doi.org/10.1002/acn3.307

Ejemplares similares